KINETICfinder: A disruptive method to determine kinetic profiles in drug discoveries

Informations projet

KINETICfinder

N° de convention de subvention: 867659

DOI

10.3030/867659

Projet clôturé

Date de signature de la CE 24 Mai 2019

Date de début 1 Juin 2019

Date de fin 30 Novembre 2019

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

ENZYMLOGIC SL
Spain

Periodic Reporting for period 1 - KINETICfinder (KINETICfinder: A disruptive method to determine kinetic profiles in drug discoveries)

Période du rapport: 2019-06-01 au 2019-11-30

Résumé du contexte et des objectifs généraux du projet

Bringing a new drug to the market costs €2,600M and takes 12 years. Around 80% of drugs under research do not reach clinical trials. Pharma industry has selected only those potential drugs that have high financial return. There are 26 million people suffering from Alzheimer's, which leads to $600M in expenses per year. Diabetes killed 1.6 million people in 2016. Deaths due to dementias doubled from 2000, making it the 5th leading cause of global deaths in 2016. These trends show the need for a game changing solution that will improve patients’ life expectancy and contribute to a more sustainable healthcare system. ENZYMLOGIC aims to become a leading company in the niche of kinetic drug analysis. It has validated a reduction of time and cost by 50% in the pathway of a new drug from research to market.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

Enzymlogic has validated the technical feasibility of KINETICfinder where GPCR was implemented. The robustness and sensitivity achieved are above the standard criteria in the pharma industry. The accuracy and reproducibility of data has been demonstrated and it is an environmentally friendly platform, reducing significantly the number of animals used in preclinical trials and avoiding the use of contaminating radioactive residues. In the business viability, Enzymlogic has validated the market niche of drug development analysis from an early stage worldwide, already having 3 customer of the top-10 global market. The area of biotechnological drugs also has a significant growth of 14.1%. Drugs are regarding cancer-targeted therapies and Alzheimer's disease as the most researched. The scalability analysis shows that due to the highly processability of the process. The revenue model based on a “Pay per Service” procedure has been validated, but some other revenues approaches will not be developed. A high-skilled commercial team will be required to keep the relationships with worldwide top-twenty Enzymlogic’s customers. In addition, the IPR strategy has been developed to protect further stages and once the technical, economic and commercial viability has been proven, Enzymlogic has already a complete business plan.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Actions are expected to demonstrate clear exploitation potential and socioeconomic benefits for patients and sustainable health systems. KINETICfinder will contribute to solve the following socio-economic challenges, facilitating new fast routes to develop drugs for complex diseases and overcome resistances. Aditionally, KINETICfinder is environmentally-friendly.

ipr-strategy.jpg